Clinical trialNCT04276597WithdrawnPhase 2Interventional

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

SponsorExcel Diagnostics and Nuclear Oncology CenterEnrollment0Neuroendocrine Breast TumorNeuroendocrine Carcinoma MetastaticNeuroendocrine Neoplasm of OvaryNeuroendocrine Skin CarcinomaNeuroendocrine TumorsParaganglioma+4 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Determine the safety and effectiveness of Lu-177 DOTATOC in adult subjects with somatostatin receptor-expressing Pulmonary, Pheochromocytoma, Paraganglioma, Unknown primary, and Thymus neuroendocrine tumors or any other non-.GEP-NET. The treatment regimen will consist of 4 doses of 200 (±10%) mCi 177Lu-DOTATOC administered at 8+/- 1-week intervals.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Afshin Shafie, MD
Excel Diagnostics and Nuclear Oncology Center
Study Director
clinicaltrials.gov ↗
Ayman Gaber, MD
Excel Diagnostics and Nuclear Oncology Center
Study Director
clinicaltrials.gov ↗
Ebrahim Delpassand, MD
Excel Diagnostics and Nuclear Oncology Center
Principal Investigator
clinicaltrials.gov ↗
Rodolfo Nunez, MD
Excel Diagnostics and Nuclear Oncology Center
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Excel Diagnostics and Nuclear Oncology Center
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Lutetium Lu177 Edotreotide

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 4 Mar 2020
Primary completion: 15 Jul 2021
Completion: 15 Jul 2021
Last update posted: 10 Mar 2023
Registered enrollment: 0
Registry id: NCT04276597

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.